Compare Tractor Supply Co (TSCO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tractor Supply Co vs Travere Therapeutics Inc. Common Stock — how do they compare? Tractor Supply Co trades at $32.67 (market cap $17.56B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Tractor Supply Co is far larger — about 3.6× Travere Therapeutics Inc. Common Stock's market cap, and Tractor Supply Co pays a 2.85% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tractor Supply Co for 89 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TSCO | TVTX | |
|---|---|---|
Market Cap | $17.56B | $4.88B |
Volume | 9,523,235 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $56.37 | $67.52 |
52-Week Low | $29.14 | $26.79 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $23.87B | $5.01B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tractor Supply (TSCO) trades at $32.74, down 2.12% today amid recent earnings misses. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Fundamentally, the company maintains solid profitability with 36.46% gross margins and 39.51% ROE, though revenue growth has slowed to 4.2% annually. Recent news highlights dividend sustainability concerns after two consecutive quarterly misses and a 17-year dividend growth streak.
Outlook remains cautious with analyst consensus at $36.76 target (12% upside) but recent institutional selling and earnings disappointments create near-term headwinds. Key risks include competitive pressures, rural consumer spending volatility, and margin compression from 7.66% to 6.42% over four years. The dividend yield of 0.73% provides income support while growth initiatives target pet care and logistics optimization.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
